Metabolite Profiling of LADA Challenges the View of a Metabolically Distinct Subtype.
case_control · Level III
Where this comes from
- Record sourced from PubMed, PMID 27913577.
- Also identified by DOI 10.2337/db16-0779.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Latent autoimmune diabetes in adults (LADA) usually refers to GAD65 autoantibodies (GADAb)-positive diabetes with onset after 35 years of age and no insulin treatment within the first 6 months after diagnosis. However, it is not always easy to distinguish LADA from type 1 or type 2 diabetes. In this study, we examined whether metabolite profiling could help to distinguish LADA (<i>n</i> = 50) from type 1 diabetes (<i>n</i> = 50) and type 2 diabetes (<i>n</i> = 50). Of 123 identified metabolites, 99 differed between the diabetes types. However, no unique metabolite profile could be identified for any of the types. Instead, the metabolome varied along a C-peptide-driven continuum from type 1 diabetes via LADA to type 2 diabetes. LADA was more similar to type 2 diabetes than to type 1 diabetes. In a principal component analysis, LADA patients overlapping with type 1 diabetes progressed faster to insulin therapy than those overlapping with type 2 diabetes. In conclusion, we could not find any unique metabolite profile distinguishing LADA from type 1 and type 2 diabetes. Rather, LADA was metabolically an intermediate of type 1 and type 2 diabetes, with those patients closer to the former showing a faster progression to insulin therapy than those closer to the latter.
Medical subject headings
- Diabetes Mellitus, Type 1
- Diabetes Mellitus, Type 2
- Latent Autoimmune Diabetes in Adults
- Metabolome